Amino Acid, Peptide, or Protein
Court Rejects HHS Motion to Dismiss Lawsuit Over US Childhood Vaccine Overhaul as Clinician Groups Push Forward
childhood vaccine overhaul; HHS; lawsuit; ACIP; AAP; CDC; RFK Jr.; immunization schedule
Exciva Raises $59M Series B to Fund Phase 2 Trial of Deraphan for Alzheimer’s Agitation
Exciva; Series B; $59M; Alzheimer’s; agitation; Deraphan; Phase 2; neuropsychiatry
Moderna and Merck Report Sustained 49% Risk Reduction in Recurrence or Death with mRNA-Keytruda Combo at Five Years in Melanoma Trial
Moderna; Merck; Keytruda; intisemeran autogene; mRNA-4157; melanoma; recurrence-free survival; Phase 2b
AstraZeneca Acquires Complete Global Rights to AbelZeta’s C-CAR031 CAR-T Therapy for Up to $630 Million
AstraZeneca; AbelZeta; C-CAR031; CAR-T; GPC3; China rights; $630M; hepatocellular carcinoma; HCC
Genmab and AbbVie’s Epcoritamab Misses Overall Survival Endpoint but Meets PFS in Phase 3 DLBCL Trial
Genmab; AbbVie; epcoritamab; Epkinly; EPCORE DLBCL-1; Phase 3; DLBCL; lymphoma; overall survival; progression-free survival
N.Y. Attorney General Sues Former Emergent BioSolutions CEO Robert Kramer for Insider Trading
insider trading; Emergent BioSolutions; Robert Kramer; New York AG; Letitia James; COVID-19 vaccine; AstraZeneca; stock sales
Teva Launches First Generic GLP-1 for Weight Loss Amid Ongoing Market Developments
generic GLP-1; Teva; liraglutide; Saxenda; FDA approval; weight loss drugs
Novo Nordisk Foundation Commits Over $850M to Danish Life Science Incubator BII Over Next Decade
Novo Nordisk Foundation; BII; life science incubator; $850M; biotech startups; Denmark
JPM26 Day 3: Sanofi CEO on RSV Scrutiny and Regeneron Dupixent Defense
JPM26; Sanofi; RSV; Beyfortus; Paul Hudson; FDA; vaccines; Dupixent; Regeneron
Caldera Therapeutics Launches with $112.5M Funding for China-Licensed IBD Bispecific Antibody
Caldera Therapeutics; IBD; bispecific antibody; $112.5M funding; Qyuns Therapeutics; CLD-423